• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Parsey Merdad

    4/29/25 4:49:46 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVBP alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Parsey Merdad

    (Last) (First) (Middle)
    C/O ARRIVENT BIOPHARMA, INC.
    18 CAMPUS BOULEVARD, SUITE 100

    (Street)
    NEWTOWN SQUARE PA 19073

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/28/2025
    3. Issuer Name and Ticker or Trading Symbol
    ArriVent BioPharma, Inc. [ AVBP ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24.1 - Power of Attorney
    No securities are beneficially owned.
    /s/ James Kastenmayer, Attorney-in-Fact for Merdad Parsey 04/29/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AVBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVBP

    DatePrice TargetRatingAnalyst
    3/20/2025$37.00Buy
    B. Riley Securities
    3/10/2025$45.00Buy
    Guggenheim
    7/22/2024$35.00Outperform
    Oppenheimer
    4/30/2024$25.00Buy
    H.C. Wainwright
    2/20/2024$35.00Buy
    Jefferies
    2/20/2024$27.00Buy
    Goldman
    2/20/2024$30.00Buy
    Citigroup
    More analyst ratings

    $AVBP
    SEC Filings

    See more
    • SEC Form 10-Q filed by ArriVent BioPharma Inc.

      10-Q - ArriVent BioPharma, Inc. (0001868279) (Filer)

      5/12/25 9:35:57 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ArriVent BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

      5/12/25 8:00:19 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ArriVent BioPharma Inc.

      DEFA14A - ArriVent BioPharma, Inc. (0001868279) (Filer)

      4/28/25 4:20:18 PM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ArriVent BioPharma Reports First Quarter 2025 Financial Results

      Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results

      5/12/25 8:00:00 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

      NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc. "Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies acr

      4/28/25 8:00:00 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ArriVent BioPharma Reports Full Year 2024 Financial Results

      First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for firmonertinib in first-line NSCLC harboring EGFR exon 20 insertion mutations achieved target enrollmentSelected next-generation ADC candidate ARR-002 for IND enabling studiesCash and cash equivalents of $266.5 million as of December 31, 2024 NEWTOWN SQUARE, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financia

      3/3/25 7:00:00 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on ArriVent BioPharma with a new price target

      B. Riley Securities initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $37.00

      3/20/25 7:59:08 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on ArriVent BioPharma with a new price target

      Guggenheim initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $45.00

      3/10/25 7:18:09 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on ArriVent BioPharma with a new price target

      Oppenheimer initiated coverage of ArriVent BioPharma with a rating of Outperform and set a new price target of $35.00

      7/22/24 7:50:34 AM ET
      $AVBP
      Biotechnology: Pharmaceutical Preparations
      Health Care